<DOC>
	<DOCNO>NCT01276041</DOCNO>
	<brief_summary>The purpose study see combination drug help treat type cancer . One drug chemotherapy agent call paclitaxel ( Taxol® ) . Paclitaxel give every week vein . Although weekly schedule paclitaxel include label , schedule dose weekly paclitaxel study proven effective old standard schedule . The two work HER2 . One call trastuzumab ( Herceptin® ) commonly give woman early HER2 positive breast cancer advance HER2 positive breast cancer spread part body . Trastuzumab give vein every 3 week ( every week doctor 's discretion ) . The third drug , pertuzumab , investigational drug . It approve Food Drug Administration . It give study 800 people . It effective treat HER2 positive breast cancer . Pertuzumab give every 3 week vein . This study look effectiveness three drug together .</brief_summary>
	<brief_title>Paclitaxel , Trastuzumab , Pertuzumab Treatment Metastatic HER2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age ≥18 Stage IV HER2 ( + ) breast cancer . Histologically document HER2 ( + ) breast cancer define IHC 3+ FISH amplification ≥ 2.0 primary metastatic site ; result local lab acceptable . ( Optional tumor sample collection primary metastatic site may obtain HER2 test MSKCC ) . ECOG performance 0 1 ( Appendix A ) 01 prior treatment metastatic setting ( ie : hormone , chemotherapy , biologic , target agent ) . Prior anthracycline , paclitaxel , trastuzumab adjuvant setting allow . If patient one trastuzumabbased treatment metastatic set give break ( even intermittently ) partner drug give trastuzumab continue trastuzumab alone , would still consider one treatment . For example , patient give paclitaxel + trastuzumab later continue trastuzumab alone restart paclitaxel + trastuzumab ( physician 's discretion reason ) , regimen paclitaxel + trastuzumab follow trastuzumab alone ( follow paclitaxel + trastuzumab ) may consider one treatment . Measurable nonmeasurable disease . Measurable lesion define measure accurately least one diameter , 20 mm use conventional imaging technique ( include incremental CT ) 10 mm use spiral CT equipment lymph node 15 mm along short axis . Nonmeasurable lesion lesion , include small lesion ( long diameter &lt; 10mm pathological lymph nod 10 less 15mm along short axis , bony metastasis , leptomeningeal disease , ascites , pleural/pericardial effusion , inflammatory breast cancer , lymphangitis carcinomatosis , heavily calcify cystic/necrotic lesion . LVEF ≥ 50 % Hematologic parameter : white blood cell ( WBC ) count ≥ 3000/ul , absolute neutrophil count ( ANC ) ≥1500/ul , platelet ≥ 100,000/ul , hemoglobin ≥ 10.0 g/dl Nonhematologic parameter : bilirubin ≤ 1.5 mg/dl , AST/ALT ≤ 2.5 x upper limit normal ( ULN ) , alkaline phosphatase ≤ 5 x ULN . Creatinine ≤ 1.5 mg/dl Patients stable treated brain lesion duration ≥ 2 month may enrol . History prior cardiac morbidity within 12 month ( unstable angina , myocardial infarction , CHF , uncontrolled ventricular arrhythmia ) Prior pertuzumab History prior ≥ G 3 hypersensitivity ( HSR ) toxicity trastuzumab warrant permanent cessation antibody History prior ≥ G 3 HSR toxicity paclitaxel warrant permanent cessation chemotherapy &gt; G 2 peripheral neuropathy Patients history chronic hepatitis B C exclude study paclitaxel potentially hepatotoxic Pregnant patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MAB 2C4 ( PERTUZUMAB )</keyword>
	<keyword>MAB HER 2 ( HERCEPTIN ) ( TRASTUZUMAB )</keyword>
	<keyword>TAXOL ( PACLITAXEL )</keyword>
	<keyword>10-142</keyword>
	<keyword>Stage IV HER2 ( + ) breast cancer</keyword>
</DOC>